Aktis Oncology
Erik Chelius serves as a Scientific Advisor for Aktis Oncology. Erik spent more than 20 years working in both the development and manufacturing divisions of Eli Lilly & Co., where he contributed to the production chemistry and manufacture of products such as Gemzar®, Evista®, Alimta®, and Cialis®. In 2012 he joined Endocyte, Inc., as the Vice President of Chemistry, Manufacturing, and Control where he played a key role in developing and securing the Phase 3 clinical trial supply chain for Lu-PSMA-617. He has been an independent consultant since Novartis purchased Endocyte in 2019.
Erik holds a PhD in Physical Organic Chemistry from Northwestern University.
This person is not in the org chart
This person is not in any offices
Aktis Oncology
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.